Navigation Links
Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
Date:5/28/2013

ared to $1.1 million for the first quarter of 2012. The amounts for the first quarter of 2013 and 2012 include approximately $0.1 million and $0.1 million of non-cash stock-based compensation expense, respectively. The increase in General & Administrative expenses is largely attributable to legal and consulting costs required for intellectual property filings.
  • As of March 31, 2013, cash and cash equivalents were $14.4 million. This amount does not include the approximate $58 million in net proceeds from the IPO, which closed in April 2013, nor any of the $12.5 million debt facility, which remains undrawn.
  • About Omthera Pharmaceuticals, Inc.Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for dyslipidemia and the treatment of cardiovascular disease. Epanova, currently the Company's sole product candidate, is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-3 and omega-6 fatty acids, with EPA, DHA, and docosapentaenoic acid being the most abundant forms of omega-3 fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product.

    Forward-Looking Statements:This press release includes forward-look
    '/>"/>

    SOURCE Omthera Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
    2. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
    3. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
    4. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
    5. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
    6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    7. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    8. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
    9. Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Worth $825 Million by 2017
    10. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
    11. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, ... to its investment in development and manufacturing capabilities with ... Karl Mueller , Particle Sciences, Associate Director Clinical ... pace adding clean room square footage, equipment and staff ... clients.  The company now has over 6000ft 2 ...
    (Date:9/2/2014)... Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation (ODEV) ... Stem, the latest addition to its growing hip ... intended for use in total hip arthroplasty and ... Alpine was developed based ... ODEV,s engineers worked closely with a select team ...
    (Date:9/2/2014)... NEW YORK , September 2, 2014 ... regarding WellPoint Inc. (NYSE: WLP ), Tekmira ... (NYSE: ZTS ), Sanofi SA (NYSE: ... wealth members receive these notes ahead of publication. To ... http://www.analystsreview.com/6142-100free . , ,-- ,WellPoint Inc. Research Reports ,WellPoint ...
    Breaking Medicine Technology:Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
    (Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
    (Date:9/2/2014)... (PRWEB) September 02, 2014 The use ... blood thinners is growing at a rapid pace, even ... mount in courts around the U.S., Bernstein Liebhard LLP ... Journal of Medicine, within a year of its 2011 ... Xarelto as warfarin, a blood thinner that has been ...
    (Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
    (Date:9/2/2014)... a large population-based study of randomly selected participants ... (MCI) occurred twice more often in individuals diagnosed ... association was only observed in middle-aged participants (50-65 ... association vanished. This study is published in the ... concept of MCI describes an intermediate state between ...
    (Date:9/2/2014)... Medex Analytic Services is delighted ... in Coral Springs, Fla. due to their greater than ... objectives for the 2014 year by distinguishing Medex in ... requested a higher level of service and professionalism in ... and the industry has responded.” , The location of ...
    Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
    ... known that diabetes, one of the world’s leading debilitating diseases, ... 194 million adults worldwide. Therefore, there is a huge demand ... the patients. ,There are two types of diabetes: ... for approximately 5% of all the cases. This type is ...
    ... been used by a pediatric research team to scrutinize ... small defects that lead to genetic diseases //. ... detect these abnormalities, the new research may lead to ... that lead to mental retardation. ,“For years, ...
    ... in Australia have been linked to the work place each ... //and the University of Sydney has shown that about 1,600 ... asbestos, passive smoking, fumes and exhaust at work. Several cases ... a work related origin. ,Professor Lin Fritschi, lead ...
    ... are planning to demand the government to levy heavy tax ... mainly combat the nation's obesity epidemic. The issue mainly addresses ... of salt added to burgers and processed foods. The ... to obesity. Due to this the sales of soft drinks ...
    ... CHICAGO - Abnormal glucose metabolism, which occurs when the ... twice as common among patients //with chronic nerve dysfunction ... may be a risk factor for the condition, according ... in the August 2006 print issue of Archives of ...
    ... have left its impact on the six million care givers in ... because of caring //. ,The survey revealed that only ... GP while 90% of them considered that they should be offered ... that their own health problems affected their ability to care. Besides ...
    Cached Medicine News:Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 3Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 4Health News:Work Related Cancer on the Rise in Australia 2Health News:Abnormal Glucose Metabolism May Contribute to Chronic Nerve Disorder 2Health News:Care Workers Need Some Care Too 2
    Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
    The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
    Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
    For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
    Medicine Products: